Microviable Therapeutics attends Bio Europe 2019, the most important continental forum in the field of Biotechnology

Microviable Therapeutics and the Asturian biotechs Entrechem and Dreamgenics participate in the 25th edition of Bio Europe 2019 (Hamburg), the most important continental event in the field of life sciences and that contacts companies with interested investors.

Microviable meets potential customers and investors in order to enhance the company’s development. In particular, it seeks business and partnerships with companies focused on the analysis and treatment of the human microbiome.

The Asturian biotech companies are supported by CEEI ASTURIAS y ASTUREX. Sociedad de Promoción Exterior Principado de Asturias, S.A.

 

Related news

Participación asturiana en la gran cita biotecnológica de HamburgoLa Nueva España

Tres empresas biotecnológicas asturianas en Bio Europe 2019El Digital De Asturias

El Principado facilita la presencia de tres empresas Biotecnológicas asturianas en el mayor encuentro europeo del sectorORT

Tres empresas asturianas estarán presentes en Bio-Europe 2019. Conecta Industria

Microviable Therapeutics participates in the ninth edition of Gut Microbiota For Health Summit (GMFH2020)

Microviable Therapeutics, through our CEO Rafael Martínez Permuy, was part of the “Gut Microbiota for Health World Summit” (#GMFH2020) that was held on March 7 and 8 in Madrid, a great international event on microbiota that has recorded 200 attendees in person plus some others by videoconference (videoconference due to travel restrictions).

Read More

Microviable Therapeutics, as part of CSIC stand, participates at the European Forum Transferie 2020

Microviable Therapeutics was in the group of technology-based companies that the CSIC presented at Transfiere 2020, the European Forum for Science, Technology and Innovation, which was held in Malaga on 12 and 13 February.

During the event, Rafael Martinez Permuy, CEO at Microviable, commented that the microbiota is already related to about 120 diseases and points out the need for a gut microbiota storage system for future therapeutic applications in the line of the “library” that the company is creating.

Rafael highlighted also the sale of more than 600 Gutalive kits for the collection of stool samples in anaerobiosis and the EC Seal of Excellence in H2020 received by the company.

View more at Infosalus